Amanda L. Skarlupka

Amanda L. Skarlupka

Auto-generated profile, based on publicly available information

Amanda L. Skarlupka

Division of Cancer Prevention, National Cancer Institute , Bethesda, MD

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
JEJeffrey Ecker
Jeffrey Ecker
Greg KirchenbaumGreg Kirchenbaum
Greg Kirchenbaum
SPSpencer Pierce
Spencer Pierce
ASAmanda L. Skarlupka
Amanda L. Skarlupka
Rodrigo Bessa AbreuRodrigo Bessa Abreu
Rodrigo Bessa Abreu
Giuseppe Andrea SauttoGiuseppe Andrea Sautto
Giuseppe Andrea Sautto
Influenza viruses infect millions of people each year, resulting in significant morbidity and mortality in the human population. Therefore, generation of a universal influenza virus vaccine is an urgent need and would greatly benefit public health. Recombinant protein technology is an established vaccine platform and has resulted in several commercially available vaccines. Herein, we describe the approach for developing stable transfected human cell lines for the expression of recombinant influenza virus hemagglutinin (HA) and recombinant influenza virus neuraminidase (NA) proteins for the purpose of in vitro and in vivo vaccine development. HA and NA are the main surface glycoproteins on influenza virions and the major antibody targets. The benefits for using recombinant proteins for in vitro and in vivo assays include the ease of use, high level of purity and the ability to scale-up production. This work provides guidelines on how to produce and purify recombinant proteins produced in mammalian cell lines through either transient transfection or generation of stable cell lines from plasmid creation through the isolation step via Immobilized Metal Affinity Chromatography (IMAC). Collectively, the establishment of this pipeline has facilitated large-scale production of recombinant HA and NA proteins to high purity and with consistent yields, including glycosylation patterns that are very similar to proteins produced in a human host.

22 March 2024 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
PDF file
WRWendy S. Rubinstein
Wendy S. Rubinstein
CPChristos Patriotis
Christos Patriotis
ADAnthony Dickherber
Anthony Dickherber
PHPaul K. J. Han
Paul K. J. Han
HKHormuzd A. Katki
Hormuzd A. Katki
LMLori M. Minasian
Lori M. Minasian
Multicancer detection (MCD) tests use a single, easily obtainable biospecimen, such as blood, to screen for more than one cancer concurrently. MCD tests can potentially be used to improve early cancer detection, including cancers that currently lack effective screening methods. However, these tests have unknown and unquantified benefits and harms. MCD tests differ from conventional cancer screening tests in that the organ responsible for a positive test is unknown, and a broad diagnostic workup may be necessary to confirm the location and type of underlying cancer. Among two prospective studies involving greater than 16,000 individuals, MCD tests identified those who had some cancers without currently recommended screening tests, including pancreas, ovary, liver, uterus, small intestine, oropharyngeal, bone, thyroid, and hematologic malignancies, at early stages. Reported MCD test sensitivities range from 27% to 95% but differ by organ and are lower for early stage cancers, for which treatment toxicity would be lowest and the potential for cure might be highest. False reassurance from a negative MCD result may reduce screening adherence, risking a loss in proven public health benefits from standard‐of‐care screening. Prospective clinical trials are needed to address uncertainties about MCD accuracy to detect different cancers in asymptomatic individuals, whether these tests can detect cancer sufficiently early for effective treatment and mortality reduction, the degree to which these tests may contribute to cancer overdiagnosis and overtreatment, whether MCD tests work equally well across all populations, and the appropriate diagnostic evaluation and follow‐up for patients with a positive test.

22 December 2020 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
ZRZachary Beau Reneer
Zachary Beau Reneer
PJParker J. Jamieson
Parker J. Jamieson
ASAmanda L. Skarlupka
Amanda L. Skarlupka
YHYing Huang
Ying Huang
TRTed Ross
Ted Ross
H2N2 influenza has caused at least one pandemic in the past. Given that individuals born after 1968 have not been exposed to H2N2 influenza viruses, a future pandemic caused by H2 influenza is likely. An effective H2 influenza vaccine would need to elicit broadly cross-reactive antibodies to multiple H2 influenza viruses. Choosing a wild-type virus to create a vaccine may elicit a narrow immune response and not protect against multiple H2 influenza viruses. COBRA H2 HA vaccines were developed and evaluated in mice along with wild-type H2 HA vaccines. Multiple COBRA H2 HA vaccines protected mice from all three viral challenges and produced broadly cross-reactive neutralizing antibodies to H2 influenza viruses.

9 January 2023 in Viruses
Verified
Journal Article
Open access
PDF file
ASAmanda L. Skarlupka
Amanda L. Skarlupka
XZXiaojian Zhang
Xiaojian Zhang
UBUriel Blas-Machado
Uriel Blas-Machado
SSSpencer F. Sumner
Spencer F. Sumner
TRTed Ross
Ted Ross
The influenza neuraminidase (NA) is a promising target for next-generation vaccines. Protection induced by vaccination with the computationally optimized broadly reactive NA antigen (N1-I COBRA NA) was characterized in both influenza serologically naive and pre-immune ferret models following H1N1 (A/California/07/2009, CA/09) or H5N1 (A/Vietnam/1203/2004, Viet/04) influenza challenges. The N1-I COBRA NA vaccine elicited antibodies with neutralizing ELLA activity against both seasonal and pandemic H1N1 influenza, as well as the H5N1 influenza virus. In both models, N1-I COBRA NA-vaccinated ferrets that were challenged with CA/09 virus had similar morbidity (weight loss and clinical symptoms) as ferrets vaccinated with the CA/09 HA control vaccine. There were significantly reduced viral titers compared to the mock-vaccinated control animals. Ferrets vaccinated with N1-I COBRA NA or Viet/04 NA vaccines were protected against the H5N1 virus infection with minimal clinical symptoms and negligible weight loss. In contrast, ferrets vaccinated with the CA/09 NA vaccine lost ~10% of their original body weight with 25% mortality. Vaccination with either HA or NA vaccines did not inhibit contact transmission of CA/09 virus to naïve cage mates. Overall, the N1-I COBRA vaccine elicited protective immune responses against both H1N1 and H5N1 infections and partially mitigated disease in contact-transmission receiving ferrets. These results indicate that the N1-I COBRA NA performed similarly to the CA/09 HA and NA positive controls. Therefore, the N1-I COBRA NA alone induces protection against viruses from both H5N1 and H1N1 subtypes, indicating its value as a vaccine component in broadly protective influenza vaccines.

10 April 2019 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
KDKalyan Kumar Dewan
Kalyan Kumar Dewan
DTDawn L Taylor-Mulneix
Dawn L Taylor-Mulneix
LCLaura L Campos
Laura L Campos
ASAmanda L Skarlupka
Amanda L Skarlupka
SWShannon M Wagner
Shannon M Wagner
ERIC HARVILLERIC HARVILL
ERIC HARVILL
Infection and inflammation of the middle ears that characterizes acute and chronic otitis media (OM), is a major reason for doctor visits and antibiotic prescription, particularly among children. Nasopharyngeal pathogens that are commonly associated with OM in humans do not naturally colonize the middle ears of rodents, and experimental models in most cases involve directly injecting large numbers of human pathogens into the middle ear bullae of rodents, where they induce a short-lived acute inflammation but fail to persist. Here we report that Bordetella pseudohinzii, a respiratory pathogen of mice, naturally, efficiently and rapidly ascends the eustachian tubes to colonize the middle ears, causing acute and chronic histopathological changes with progressive decrease in hearing acuity that closely mimics otitis media in humans. Laboratory mice experimentally inoculated intranasally with very low numbers of bacteria consistently have their middle ears colonized and subsequently transmit the bacterium to cage mates. Taking advantage of the specifically engineered and well characterized immune deficiencies available in mice we conducted experiments to uncover different roles of T and B cells in controlling bacterial numbers in the middle ear during chronic OM. The iconic mouse model provides significant advantages for elucidating aspects of host-pathogen interactions in otitis media that are currently not possible using other animal models. This natural model of otitis media permits the study of transmission between hosts, efficient early colonization of the respiratory tract, ascension of the eustachian tube, as well as colonization, pathogenesis and persistence in the middle ear. It also allows the combination of the powerful tools of mouse molecular immunology and bacterial genetics to determine the mechanistic basis for these important processes. Bacterial infections of the middle ears (otitis media), particularly among children, is a global problem, causing fever, pain, conductive hearing loss and possible complications due to persistence/recurrence. Current understanding is poor, and advances are slowed by limitations of experimental systems that, for example, inject large numbers of human pathogens into the middle ears of rodents. Such approaches introduce tissue damage, bypass progression from natural colonization to disease and these pathogens fail to persist as chronic infections, the period when complications associated with otitis media begin to increase. Here we report that Bordetella pseudohinzii, a gram-negative bacterium we previously identified as a respiratory pathogen of mice, naturally and extremely efficiently colonizes and persists in their middle ears, causing acute and chronic histopathological changes that closely mimic otitis media in humans. Laboratory mice experimentally infected with low bacterial numbers by droplet inhalation consistently have their middle ears colonized and subsequently transmit the bacterium to cage mates. The natural B. pseudohinzii-mouse model provides an experimental system in which to study aspects of the progression from earliest colonization, infection, spread, pathogenesis to long-term persistence as well as providing the tools of immune-deficient mice that can reveal the contributions of each aspect of immunity in controlling and clearing chronic middle ear infection.

8 April 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
ASAmanda L. Skarlupka
Amanda L. Skarlupka
TRTed Ross
Ted Ross
The initial exposure to influenza virus usually occurs during childhood. This imprinting has long-lasting effects on the immune responses to subsequent infections and vaccinations. Animal models that are used to investigate influenza pathogenesis and vaccination do recapitulate the pre-immune history in the human population. The establishment of influenza pre-immune ferret models is necessary for understanding infection and transmission and for designing efficacious vaccines.